Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Lu Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3048-1135; OpenAlex author ID A5017873319. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Bruceine A abrogates pancreatic cancer metastasis by suppressing PFKFB4-glycolysis-EMT axis. Co-author DOI 10.1016/j.phymed.2025.157665↗
  2. Enhanced ROS-Boosted Phototherapy against Pancreatic Cancer via Nrf2-Mediated Stress-Defense Pathway Suppression and Ferroptosis Induction. Co-author DOI 10.1021/acsami.1c22861↗
  3. A novel P38α MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity. Co-author DOI 10.1016/j.csbj.2021.06.011↗
  4. Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. Co-author DOI 10.1016/j.phrs.2021.105658↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weiwei Tao · 4 shared papers, 2021–2026 · strength 0.70
  2. Ming Zhao · 4 shared papers, 2021–2026 · strength 0.70
  3. Pengfei Zhang · 3 shared papers, 2021–2022 · strength 0.39
  4. Wei Liu · 1 shared paper, 2026 · strength 0.32
  5. Si‐Nan Lu · 1 shared paper, 2026 · strength 0.32
  6. Chengbin Yang · 2 shared papers, 2021 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.